Additional European Equity News
Newsquawk ·
Burberry (BRBY LN) - Q4 2026 (GBP): Revenue 2.42bln (prev. 2.46bln Y/Y), Adj. Op. Profit 160mln (prev. 26mln Y/Y). Retail comp sales +5% (exp. +4.6%). CEO : “We’ve returned to profitable comparable sales growth, with a strong fourth quarter driven by momentum in Greater China and Americas. Our strategy is working and there are clear opportunities for further growth”. By Region: Returned to comparable sales growth from Q2, with sequential improvement throughout the year; particular strength in Greater China and Americas, both up double digit in Q4. FY27 Outlook: “In FY27 we expect to make further progress on our financial ambitions, including delivering revenue growth and margin expansion”. Wholesale is expected to grow by mid-single digit percentage in H1 FY27. Board Update: Chair Gerry Murphy has decided to retire, effective November 2026. (Burberry) Ipsen (IPN FP) - Co. unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI, at the SCALE Symposium. Phase II data in glab
AI 시장 분석
Burberry (BRBY LN) reported Q4 revenue of 2.42bln (previous 2.46bln Y/Y) and adjusted operating profit of 160mln (previous 26mln Y/Y), with retail like-for-like sales up 5%, slightly above the 4.6% expectation. Demand recovery was particularly pronounced in Greater China and the Americas, where quarterly double-digit growth led management to target revenue growth and margin expansion for FY27. Wholesale is expected to see mid-single-digit unit growth in H1 FY27, indicating a mixed channel recovery. Separately, chairman Gerry Murphy's announced retirement in November 2026 may act as a governance variable. Ipsen (IPN FP) unveiled the first-in-class recombinant neuroinhibitor corabotase at the SCALE symposium, suggesting Phase II data and drawing interest in biotech, aesthetic, and neurological treatment areas.
상승 영향
- Luxury (Fashion & Luxury Goods) — Burberry's Q4 profitability recovery and strong demand in Greater China and the Americas raise expectations for sales and margin improvement across the sector.
- Biotech (Neuroinhibitors/RNI) — Ipsen's reveal of first-in-class corabotase and Phase II progress could prompt a revaluation of neuroinhibitor and aesthetic treatment pipelines, positively affecting investor sentiment.
- Travel retail & duty-free — Consumption recovery in Greater China and the Americas should translate into higher spending in international travel and duty-free channels, benefiting duty-free and airport retail.
하락 영향
- Wholesale distribution — Burberry's expectation of only mid-single-digit unit growth in wholesale for H1 FY27 suggests limited wholesale demand recovery, posing pressure on distributors.
- Governance/Management risk — Chair Gerry Murphy's retirement introduces uncertainty around board composition and long-term strategy, which could increase share price volatility.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 65% · Bearish (Short) 35%
407 participants
Related News
- Jensen Huang's Nvidia comeback: Why the math doesn't add up
- Google’s SpaceX Stake Lost More Than $10 Billion in Value Last Quarter While Its Share Count Edged Up
- PenFed Kicks Off Holiday Celebration with Toys for Tots Drive
- Gap (GAP) Q3 2026 (USD): Adj. EPS 0.82 (exp. 0.78), Revenue 4bln (exp. 4.02bln)
- MSCI to add Anthropic to large‑cap segment of MSCI Global Standard Indexes on November 30th
- AMD Shares Tumble 7% After Short Seller Questions China Ties. Chipmaker Denies Allegations.